Global TNF Inhibitors Market Size, Status and Forecast 2019-2025

TNF (tumor necrosis factor) inhibitors are anti-inflammatory drugs. TNF inhibitors help to block the TNF alpha that occurs naturally in the body and causes inflammation. TNF drugs are used to reduce inflammation and stop disease progression by targeting the tumor necrosis factor, which is an inflammation-causing substance. TNF inhibitor drugs are employed to treat inflammatory conditions such as rheumatoid arthritis and juvenile arthritis. Generally, in the healthy person, the TNF levels remain steady. However, in a patient with rheumatoid arthritis, the level of TNF is increasing which leads to more inflammation. TNF inhibitor drugs act as blockers for TNF substances. TNF alpha blockers are highly effective in the treatment of patients with active rheumatoid arthritis. These drugs are used in patients as a conventional second-line treatments.
The adalimumab segment is likely to expand at a significant pace during the forecast period. The drug is effectively used in a broad range of pain management therapies and is widely available over the counter. Based on distribution channel, the TNF inhibitors market can be segmented into hospital pharmacy and retail pharmacy. The hospital pharmacy segment is likely to expand at a significant pace between 2017 and 2025, this is because patients with rheumatoid arthritis, arthritis give more preference to the hospitals for treatment. Increase in elderly population and rise in the prevalence of rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease are some of the factors that drive the TNF inhibitors market. According to the National Health Interview Survey, in 2016, almost 20% of the global population was reported to be suffering from chronic pain, with rheumatoid arthritis being one of the major reasons. Moreover, according to the Center for Disease Control and Prevention, by 2040, approximately 78 million (26%) of the U.S. adults are projected to have arthritis. Owing to this, the consumption of TNF inhibitor dugs is likely to increase rapidly in the near future. However, side-effects associated with the use of TNF inhibitor drugs such as skin irritation, flushing, headache, and abdominal pain are estimated to hinder the market in the next few years.
In 2018, the global TNF Inhibitors market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global TNF Inhibitors status, future forecast, growth opportunity, key market and key players. The study objectives are to present the TNF Inhibitors development in United States, Europe and China.

The key players covered in this study
Pfizer
Novartis
Boehringer Ingelheim
Amgen
BioPharma
Mochida Pharmaceutical
Hanall
...

Market segment by Type, the product can be split into
Monotherapy
Combination Therapy

Market segment by Application, split into
Skin Disease
Ankylosing Spondylitis
Gastrointestinal Disease
Rheumatoid Arthritis
Others

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global TNF Inhibitors status, future forecast, growth opportunity, key market and key players.
To present the TNF Inhibitors development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of TNF Inhibitors are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.